Notch signaling pathway component

The **Notch signaling pathway** is a highly conserved cell signaling system present in most multicellular organisms, consisting mainly of four Notch receptors (Notch1, Notch2, Notch3, Notch4 in mammals) and multiple ligands (Jagged1, Jagged2, Delta-like 1, Delta-like 3, Delta-like 4)[5][7]. Notch receptors are single-pass transmembrane receptors that, upon ligand binding from adjacent cells, undergo two proteolytic cleavages (by ADAM metalloproteases and γ-secretase), resulting in the release of the Notch intracellular domain (NICD) which translocates to the nucleus to regulate transcription of target genes[3][1][5]. The pathway is crucial in cell fate determination, stem cell maintenance, and regulation of cell proliferation and differentiation[3][2][6]. Dysregulation of Notch signaling is implicated in a wide range of diseases, notably hematological malignancies (such as T-cell acute lymphoblastic leukemia), solid tumors, and various developmental and inflammatory disorders[6][2][4][5]. Therapeutic targeting of pathway components (typically receptors or the proteases responsible for cleavage) involves agents such as γ-secretase inhibitors, monoclonal antibodies, and ligand traps, but clinical application is complicated by significant safety concerns and the pleiotropic roles of Notch signals in normal tissues[2][6]. **Caveat**: "Notch signaling pathway component" is not a standardized single target but refers to any molecular element of this pathway; for drug development or research annotation, it is best to specify the exact component, e.g., "Notch1 receptor" or "Jagged1 ligand".

Other names

Notch signaling pathwayNotch pathwayNotch receptor familyNotch receptors (Notch1/2/3/4)Delta/Serrate/Lag2 (DSL) ligand family

γ-Secretase inhibitors: block proteolytic release of NICD, preventing Notch-mediated transcription - ADAM inhibitors: block S2 cleavage and Notch receptor activation - Monoclonal antibodies: block ligand-receptor binding - Receptor decoys: sequester ligands to prevent activation - BET inhibitors: interfere with epigenetic regulation of Notch-resistance phenotypes (combination in T-ALL)